First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

PURPOSE: A novel, selective, next-generation transforming growth factor beta (TGFβ) receptor type-1 small molecule inhibitor, LY3200882, demonstrated promising preclinical data. This first-in-human trial evaluated safety, tolerability, recommended phase II dose (RP2D), pharmacokinetics, pharmacodyna...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Timothy A., Vieito, Maria, Baldini, Capucine, Sepúlveda-Sánchez, Juan Manuel, Kondo, Shunsuke, Simonelli, Matteo, Cosman, Rasha, van der Westhuizen, Andre, Atkinson, Victoria, Carpentier, Antoine F., Löhr, Mario, Redman, Rebecca, Mason, Warren, Cervantes, Andres, Le Rhun, Emilie, Ochsenreither, Sebastian, Warren, Louise, Zhao, Yumin, Callies, Sophie, Estrem, Shawn T., Man, Michael, Gandhi, Leena, Avsar, Emin, Melisi, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414273/
https://www.ncbi.nlm.nih.gov/pubmed/34548321
http://dx.doi.org/10.1158/1078-0432.CCR-21-1504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414273/
https://www.ncbi.nlm.nih.gov/pubmed/34548321
http://dx.doi.org/10.1158/1078-0432.CCR-21-1504

Ejemplares similares